Diversified healthcare company involved in diagnostics, pharmaceuticals, and biotechnology.
OPKO Health, Inc. is a diversified healthcare company with operations spanning diagnostics and pharmaceuticals across the United States, Ireland, Chile, Spain, Israel, Mexico, and other global markets. Its Diagnostics segment is anchored by BioReference Laboratories, a leading provider of laboratory testing services. BioReference Laboratories offers a wide array of diagnostic tests including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare. The segment also features a novel diagnostic instrument system designed to deliver rapid blood test results at the point of care, along with specialized services like 4Kscore prostate cancer testing.
In the Pharmaceuticals segment, OPKO Health markets Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and vitamin D insufficiency. Additionally, the company develops innovative pharmaceuticals such as OPK88004, an orally administered selective androgen receptor modulator, and OPK88003, a once-weekly peptide for type 2 diabetes and associated obesity currently in Phase IIb trials. OPKO Health's pharmaceutical endeavors also include hGH-CTP, a weekly human growth hormone injection that has completed Phase III clinical trials in collaboration with Pfizer, Inc.
Furthermore, OPKO Health engages in the development, manufacturing, marketing, and sale of a broad spectrum of pharmaceutical, nutraceutical, veterinary, and ophthalmic products. The company operates in the generics market, offering specialty APIs and importing a diverse range of pharmaceutical products across multiple therapeutic categories such as cardiovascular products, vaccines, antibiotics, hormones, and more. OPKO Health also maintains pharmaceutical platforms in strategic locations including Ireland, Chile, Spain, and Mexico.
Founded in 1991 and headquartered in Miami, Florida, OPKO Health continues to expand its global footprint and advance its portfolio of healthcare solutions through innovation, strategic partnerships, and a commitment to improving patient outcomes worldwide.